The CD40L-based approaches within this category can be subdivided into 1-recombinant protein methods utilizing CD40L mimetics and 2-gene therapy approaches, which involve introducing the CD40L gene into target cells; when CD40L enters the body, it cannot specifically distinguish tumor tissue from normal tissue. The gene discussed is CD40LG; the disease is neoplasm.